Flexion Therapeutics, Inc. (NASDAQ:FLXN) received a $39.00 target price from research analysts at Wells Fargo & Company in a note issued to investors on Monday. The firm presently has a “buy” rating on the specialty pharmaceutical company’s stock. Wells Fargo & Company’s price objective would suggest a potential upside of 80.31% from the stock’s previous close.

Several other research firms have also recently issued reports on FLXN. Northland Securities started coverage on shares of Flexion Therapeutics in a research note on Thursday, August 24th. They set an “outperform” rating and a $40.00 price target on the stock. Royal Bank Of Canada reissued a “buy” rating and issued a $44.00 target price on shares of Flexion Therapeutics in a research report on Friday, July 7th. Zacks Investment Research cut shares of Flexion Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 22nd. Needham & Company LLC raised their target price on shares of Flexion Therapeutics from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Monday, October 9th. Finally, Janney Montgomery Scott reissued a “buy” rating and issued a $35.00 target price (up from $30.00) on shares of Flexion Therapeutics in a research report on Wednesday, July 12th. One research analyst has rated the stock with a sell rating, two have given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Flexion Therapeutics presently has an average rating of “Buy” and an average price target of $88.50.

Flexion Therapeutics (NASDAQ FLXN) opened at 21.63 on Monday. The firm’s 50-day moving average is $24.68 and its 200-day moving average is $22.34. Flexion Therapeutics has a 52 week low of $15.93 and a 52 week high of $32.25. The stock’s market capitalization is $690.11 million.

Flexion Therapeutics (NASDAQ:FLXN) last released its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.80) by ($0.11). On average, equities research analysts predict that Flexion Therapeutics will post ($3.76) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Flexion Therapeutics, Inc. (FLXN) Given a $39.00 Price Target at Wells Fargo & Company” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/10/30/flexion-therapeutics-inc-flxn-given-a-39-00-price-target-at-wells-fargo-company-2.html.

In other Flexion Therapeutics news, insider Yamo Deniz purchased 3,000 shares of the business’s stock in a transaction that occurred on Friday, September 1st. The shares were purchased at an average price of $24.15 per share, for a total transaction of $72,450.00. Following the completion of the acquisition, the insider now owns 5,000 shares of the company’s stock, valued at approximately $120,750. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders purchased 5,375 shares of company stock worth $131,575 over the last three months. Corporate insiders own 15.98% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp raised its holdings in Flexion Therapeutics by 27.9% in the second quarter. Bank of New York Mellon Corp now owns 2,716,189 shares of the specialty pharmaceutical company’s stock valued at $54,921,000 after buying an additional 591,981 shares during the period. Capital World Investors raised its holdings in Flexion Therapeutics by 2.0% in the second quarter. Capital World Investors now owns 2,538,000 shares of the specialty pharmaceutical company’s stock valued at $51,318,000 after buying an additional 49,000 shares during the period. State Street Corp raised its holdings in Flexion Therapeutics by 66.3% in the second quarter. State Street Corp now owns 1,379,202 shares of the specialty pharmaceutical company’s stock valued at $27,888,000 after buying an additional 549,948 shares during the period. Vanguard Group Inc. raised its holdings in Flexion Therapeutics by 5.9% in the second quarter. Vanguard Group Inc. now owns 1,054,464 shares of the specialty pharmaceutical company’s stock valued at $21,321,000 after buying an additional 59,143 shares during the period. Finally, Wasatch Advisors Inc. raised its holdings in Flexion Therapeutics by 58.7% in the second quarter. Wasatch Advisors Inc. now owns 1,018,219 shares of the specialty pharmaceutical company’s stock valued at $20,588,000 after buying an additional 376,745 shares during the period. Hedge funds and other institutional investors own 72.31% of the company’s stock.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.